SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06990 SKB BIO-B

Trading 01-22 15:00:01

414.200

-15.200

-3.54%

High436.000	Low399.800	Vol779.40K
Open433.600	D1 Closing429.400	Amplitude8.43%
Mkt Cap96.59B	Tradable Cap67.42B	Total Shares233.19M
T/O319.81M	T/O Rate0.48%	Tradable Shares162.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":414.2,"timestamp":1769065186478,"preClose":429.4,"halted":0,"volume":779400,"delay":0,"changeRate":-0.035398230088495554,"floatShares":162769979,"shares":233185969,"eps":-1.203559,"marketStatus":"Trading","change":-15.2,"latestTime":"01-22 15:00:01","open":433.6,"high":436,"low":399.8,"amount":319808820,"amplitude":0.084304,"askPrice":414.2,"askSize":600,"bidPrice":414,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-3.508831,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769069400000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":429.4,"openAndCloseTimeList":[[1769045400000,1769054400000],[1769058000000,1769068800000]],"volumeRatio":2.417123,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990/wiki","defaultTab":"wiki","newsList":[{"id":"2604902191","title":"Sichuan Kelun-Biotech Renews R&D Procurement Deal With China Resources Kelun; Shares Slip 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604902191","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604902191?lang=en_us&edition=fundamental","pubTime":"2026-01-19 12:54","pubTimestamp":1768798473,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  entered into a new transaction framework to procure R&D-related goods from China Resources Kelun  Medicine, according to a Jan. 16 Hong Kong bourse filing.Shares of the biopharmaceutical firm were down over 5% in Monday's midday trade.The agreement covers the procurement of R&D-related drugs, consumables, and fixed assets for a term ending Dec. 31, 2028.It replaces a previous framework agreement that expired at the end of 2025.Kelun-Biotech set annual caps of nearly 10.7 million yuan for each of 2026, 2027, and 2028, the filing showed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2604944685","title":"Does Breakthrough Status For Sacituzumab Tirumotecan-Keytruda Combo Reshape Kelun-Biotech’s Oncology Strategy (SEHK:6990)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604944685","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604944685?lang=en_us&edition=fundamental","pubTime":"2026-01-17 12:34","pubTimestamp":1768624447,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical recently announced that its TROP2-directed ADC sacituzumab tirumotecan, combined with MSD’s KEYTRUDA, received Breakthrough Therapy Designation in China for first-line treatment of certain advanced non-small cell lung cancer patients, while its CEO highlighted pipeline progress and globalisation plans at the J.P. Morgan Healthcare Conference.\nThe clustering of multiple Breakthrough Therapy Designations around sacituzumab tirumotecan, alongside...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/does-breakthrough-status-for-sacituzumab-tirumotecan-keytrud","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/does-breakthrough-status-for-sacituzumab-tirumotecan-keytrud","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1585245621.USD","LU0203345920.USD","LU0238689110.USD","LU0648001328.SGD","LU2089984988.USD","LU1093756325.SGD","SG9999002232.USD","SG9999015358.SGD","LU0965509101.SGD","LU0130102774.USD","LU0058720904.USD","LU2461242641.AUD","LU1201861249.SGD","LU1934455863.HKD","IE00BN8TJ469.HKD","LU1069347547.HKD","BK4516","LU0477156953.USD","LU0861579265.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU1061106388.HKD","LU2125154778.USD","LU2468319806.SGD","LU1162221912.USD","IE00BBT3K403.USD","LU0130517989.USD","LU1066051498.USD","LU0203347892.USD","BK4585","LU1066051811.HKD","LU2361045086.USD","LU0098860793.USD","LU0006306889.USD","LU1035773651.USD","06990","LU1037948897.HKD","BK4007","IE00B4R5TH58.HKD","LU1934455277.USD","BK4559","LU1989772840.SGD","LU1974910355.USD","SG9999014575.USD","LU0196878994.USD","LU1699723380.USD","LU0985320562.USD","LU1430594728.SGD","LU2106854487.HKD","SG9999015341.SGD","LU2125154935.USD","IE000M9KFDE8.USD","LU0106261372.USD","SG9999014567.USD","SG9999002224.SGD","LU0265550359.USD","LU1116320737.USD","LU1941712348.USD","LU1066053197.SGD","SG9999013999.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2324357040.USD","BK4588","IE0002141913.USD","LU0965509283.SGD","LU0965509010.AUD","LU1023059063.AUD","LU1983299246.USD","IE0009355771.USD","LU1066051225.USD","LU0320765646.SGD","LU2112291526.USD","LU2023250843.SGD","LU0122379950.USD","SG9999001440.SGD","LU1941712264.USD","SG9999014559.SGD","LU0320765489.SGD","LU0980610538.SGD","BK4533","LU1929549753.HKD","BK1161","LU0289739699.SGD","LU1934455194.USD","LU1291159041.SGD","LU0234572021.USD","LU1989772923.USD","LU2023250504.SGD","SG9999014542.SGD","LU0211331839.USD","LU1093756168.USD","LU0070302665.USD","LU1116320901.HKD","BK4550","IE00B1BXHZ80.USD","LU0265550946.USD","LU0266013472.USD","LU1037948541.HKD","LU2361044865.SGD","LU1917777945.USD","LU1989771016.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU1571399168.USD","SGXZ57979304.SGD","SG9999001176.USD","IE00BJT1NW94.SGD","LU0208291251.USD","BK4534","LU2360032135.SGD","LU2361044949.HKD","LU0965508806.USD","IE00BSNM7G36.USD","SG9999001176.SGD"],"gpt_icon":0},{"id":"2603980939","title":"Kelun-Biotech Releases Latest Corporate Presentation Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2603980939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603980939?lang=en_us&edition=fundamental","pubTime":"2026-01-16 02:30","pubTimestamp":1768501819,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has published the presentation materials from the 44th J.P. Morgan Healthcare Conference. For more details, please refer to the \"Investor Relations-Investor Calendar\" page of the company's official website: Investor Relations-Investor Calendar.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL9MB0xr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU0196878994.USD","LU1064130708.USD","BK0060","BK0239","06990","BK1161","LU1979443071.USD","LU1934453819.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"2602300920","title":"Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300920","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602300920?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:19","pubTimestamp":1767979187,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first-line PD-L1-positive NSCLC, while its ITGB6-targeted ADC SKB105 secured IND approval for advanced solid tumors and a new global collaboration with Crescent Biopharma was announced.\nThese developments, alongside multiple ongoing registrational and Phase 3 trials and structured distribution and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4080","ADC","BK4231","06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"1116767445","title":"Kelun-Bota Biotech-B (06990) Terminates Subscription of 980 Million Yuan Bank of China Structured Deposit","url":"https://stock-news.laohu8.com/highlight/detail?id=1116767445","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116767445?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:53","pubTimestamp":1767797582,"startTime":"0","endTime":"0","summary":"Kelun-Bota Biotech-B (06990) announced the termination of its subscription to a Bank of China structured deposit II with a principal amount of RMB 980 million. The company ended this subscription on...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","BK0188","03988","LU0293314216.USD","IE00BWDBJ730.SGD","LU1048588211.SGD","LU0588546209.SGD","LU1224444064.USD","BK1560","IE00B19Z5X02.USD","LU1634259391.SGD","03143","BK0015","LU0196878994.USD","BK1231","LU0307460666.USD","IE00BQJZWZ67.USD","BK0012","06990","LU1497734951.SGD","LU1282651121.HKD","LU2097828631.EUR","LU1282651048.USD","LU1051768304.USD","BK0278","LU2097828805.USD","LU1634259557.SGD","LU1522347837.USD","LU2097828557.USD","601988","BK0028","LU0072462343.USD","SG9999006597.SGD","BK0183","LU0651947912.USD","LU2097828714.EUR","LU0651946864.USD","SG9999001093.SGD","LU0348805143.USD","LU1051769294.HKD","LU1497733631.SGD","BK1161","BK1521","LU1497733557.USD","LU1515016050.SGD"],"gpt_icon":0},{"id":"2601889804","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Subscription For BOC Structured Deposit II Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889804?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:51","pubTimestamp":1767797468,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Subscription For BOC Structured Deposit II TerminatedJan 7 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:SUBSCRIPTION FOR BOC ST","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2601801797","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Subscription for BOC Structured Deposit Ii Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601801797?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797242,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2601281568","title":"Kelun-Biotech to Present Business Progress and Innovation Strategies at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601281568","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601281568?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:45","pubTimestamp":1767753902,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is set to attend the 44th J.P. Morgan Healthcare Conference in San Francisco, California, from January 12 to 15, 2026. Dr. Michael Ge, President and CEO of Kelun-Biotech, will deliver a presentation on Thursday, January 15, 2026, at 9:30 AM Pacific Standard Time at the Westin St. Francis. The company will share its latest business progress and innovation strategies, and explore partnership opportunities at this major global healthcare industry event. A live webcast of the presentation will be available on Kelun-Biotech's official website, along with a replay for 30 days following the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLbrDM1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU1064131003.USD","BK0060","06990","LU1934453819.USD","LU1979443071.USD","BK1161","002422","BK0239","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2601828938","title":"Kelun-Biotech to Attend the 44TH J.p. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828938?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:44","pubTimestamp":1767753890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA5J2JZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234572021.USD","IE00BBT3K403.USD","LU2756315318.SGD","LU2023250330.USD","LU1267930490.SGD","LU0256863811.USD","LU0211326839.USD","LU1668664300.SGD","LU1244550494.USD","LU2054465674.USD","LU0820562030.AUD","IE00B1BXHZ80.USD","IE00BLSP4239.USD","IE00BYXW3230.USD","LU0203347892.USD","LU0868494708.USD","LU0943347566.SGD","LU1064131342.USD","LU1917777945.USD","LU1974910355.USD","LU2746668974.SGD","06990","LU1670628061.USD","IE00BJLML261.HKD","LU2756315664.SGD","LU0208291251.USD","LU2242649171.HKD","LU0106261372.USD","BK4516","BK4581","LU0345770308.USD","LU0211327993.USD","LU0267386448.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU0640476718.USD","LU0942090050.USD","LU2456880835.USD","LU1720051017.SGD","LU2746668461.USD","BK4534","LU2213496289.HKD","LU2237443978.SGD","LU2023250843.SGD","LU1914381329.SGD","LU1496350502.SGD","LU0868494617.USD","LU0265550359.USD","BK4533","LU2462157665.USD"],"gpt_icon":0},{"id":"2601840794","title":"Sichuan Kelun-Biotech Subscribes to Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2601840794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601840794?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:22","pubTimestamp":1767752534,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  subscribed to wealth management products from Bank of China  and Bank of Communications , according to a Hong Kong bourse filing Tuesday.Shares of the drug company gained over 2% in morning trade Wednesday.The firm invested 980 million yuan in a structured deposit with Bank of China for a 181-day period. The product offers an annualized floating rate of return of 0.80% or 2.15% per annum.Meanwhile, the company invested 400 million yuan in a structured deposit with Bank of Communications for a 182-day period. The product offers an annualized floating rate of return of 1.2% or 2.03% per annum.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1634259391.SGD","SG9999001093.SGD","SG9999001226.SGD","601328","LU1522347837.USD","IE00BQJZWZ67.USD","BK0020","LU1282651048.USD","LU0293314216.USD","BK0028","601988","BK1231","LU2097828714.EUR","03328","LU1048588211.SGD","LU1051768304.USD","BK0015","BK0183","LU0651947912.USD","LU1497733557.USD","LU1497734951.SGD","IE00BWDBJ730.SGD","LU0588546209.SGD","IE00B19Z5X02.USD","LU2097828557.USD","06990","03988","LU1497733631.SGD","LU1515016050.SGD","BK0278","LU0307460666.USD","BK0012","BK0187","BK1521","LU2097828631.EUR","SG9999006597.SGD","BK0188","LU1282651121.HKD","LU1224444064.USD","LU1051769294.HKD","LU0196878994.USD","LU0072462343.USD","LU0651946864.USD","LU2097828805.USD","BK1560","03143","LU1634259557.SGD","LU2097828474.EUR","LU0348805143.USD","BK1161"],"gpt_icon":0},{"id":"2601881880","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881880?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:52","pubTimestamp":1767707530,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Wealth Management ProductsJan 6 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:SUBSCRIPTIONS FOR WEALTH MANAGEMENT PROD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y617D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"1139924115","title":"SKB BIO-B (06990) Subscribes to Financial Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1139924115","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139924115?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:58","pubTimestamp":1767704296,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that on January 6, 2026, the company entered into the Bank of China Structured Deposit Agreement II, under which it agreed to subscribe to a Bank of China Structured...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2601920358","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd -  Subscriptions for Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2601920358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601920358?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:55","pubTimestamp":1767704118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y617D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2601892016","title":"Sichuan Kelun-Biotech Biopharmaceutical Co - to Subscribe for BOCOM Structured Deposit in Principal Amount of RMB400 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892016?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:55","pubTimestamp":1767704118,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y617D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2601308886","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Receives Investigational New Drug Approval for Itgb6-Targeted ADC Skb105 From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601308886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601308886?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:07","pubTimestamp":1767614833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2601988501","title":"China NMPA Approves IND for Kelun-Biotech's ITGB6-Targeted ADC SKB105","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988501","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988501?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:01","pubTimestamp":1767614474,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the Center for Drug Evaluation  of the National Medical Products Administration  of China for its Investigational New Drug  application for SKB105 , an integrin beta-6 -targeted antibody-drug conjugate . The IND approval allows Kelun-Biotech to proceed with clinical development of SKB105 for the treatment of advanced solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL3Prvmn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","06990","LU0196878994.USD","LU1064130708.USD","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","BK1161","LU2148510915.USD","BK0060","002422"],"gpt_icon":0},{"id":"2601885723","title":"FDA Clears IND for Crescent Biopharma's CR-001 Targeting Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885723","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885723?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614420,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced regulatory clearance of its Investigational New Drug  applications for two cancer therapies: CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an ITGB6-targeted antibody drug-conjugate , both intended for the treatment of advanced solid tumors. The U.S. Food and Drug Administration  cleared the IND for CR-001, enabling Crescent to proceed with a Phase 1/2 global clinical trial expected to begin in the first quarter of 2026. Additionally, Crescent’s partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., received IND approval for CR-003  from the National Medical Products Administration  of China. The collaboration grants Crescent exclusive rights to develop and commercialize CR-003 outside Greater China, while Kelun-Biotech holds exclusive rights to CR-001 in Greater China. Four clinical trials across Crescent’s portfolio are planned to commence in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL8GXSFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","06990","CBIO","LU2095319765.USD","SG9999014005.SGD","BK4112","LU1979443071.USD","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","LU0196878994.USD","BK0239","SG9999014021.USD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU1064131003.USD","SG9999014039.USD","BK4588","LU1934453819.USD","LU1064130708.USD","LU2210149790.SGD","002422","BK0060","IE00B3QW5Z07.USD","BK1161","BK4585","LU2148510915.USD","NDAQ"],"gpt_icon":0},{"id":"2601002872","title":"Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Immunotherapy Pembrolizumab for First-Line Treatment of Pd-L1-Positive Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601002872?lang=en_us&edition=fundamental","pubTime":"2026-01-05 17:28","pubTimestamp":1767605289,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA6MZFLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2601949074","title":"Sichuan Kelun-Biotech Receives Chinese Regulatory Nod to Begin Human Trials of SKB105","url":"https://stock-news.laohu8.com/highlight/detail?id=2601949074","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601949074?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:50","pubTimestamp":1767585004,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said it received Chinese regulatory approval to begin human trials of SKB105 in solid tumors, according to a Hong Kong bourse filing Sunday.Shares of the firm were up nearly 7% in morning trade Monday.Sichuan Kelun-Biotech recently granted a license to SKB105 to U.S.-based Crescent Biopharma.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2601407301","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical SAC-TMT In Combination With Immunotherapy Pembrolizumab Granted Breakthrough Therapy Designation By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601407301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601407301?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:23","pubTimestamp":1767576237,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical SAC-TMT In Combination With Immunotherapy Pembrolizumab Granted Breakthrough Therapy Designation By NMPAJan 5  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:SAC-TMT IN COMBINATION WITH IMMUNOTHERAPY PEMBROLIZUMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPAFurther company coverage: 6990.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y30A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0793},{"period":"1month","weight":0.0397},{"period":"3month","weight":0.0056},{"period":"6month","weight":0.1593},{"period":"1year","weight":1.6989},{"period":"ytd","weight":0.0948}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0238},{"period":"6month","weight":0.0471},{"period":"1year","weight":0.3222},{"period":"ytd","weight":0.0372}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.","exchange":"SEHK","name":"SKB BIO-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SKB BIO-B,06990,SKB BIO-B股票,SKB BIO-B股票老虎,SKB BIO-B股票老虎国际,SKB BIO-B行情,SKB BIO-B股票行情,SKB BIO-B股价,SKB BIO-B股市,SKB BIO-B股票价格,SKB BIO-B股票交易,SKB BIO-B股票购买,SKB BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}